All News

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

The Finnish developers of a new and tiny silicon-based timer circuit are looking for partners with application-specific engineering and marketing expertise to take the product further.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

A team of researchers at ORNL has come up with the concept of nanofermentation, and, it seems, plans to use this as a trademark.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.

Frost & Sullivan puts some flesh on the bones of the idea that nanotechnology can be a profitable tool in drug development.

The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.

The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.

Researchers at four European universities are collaborating to develop software that will help encourage the take-up of so called pervasive computing.

European biotech is a hot topic among investors. They have supported as many start-ups as in the US but have seen far from equivalent returns. So what's going on? Science|Business talks to biotechnology consultant John Hodgson.